The Blundell Group focuses on structural and computational biology and their applications to drug discovery. The experimental research seeks to understand multicomponent cell-regulatory systems, currently DNA repair through non-homologous end joining. The Group, which has defined the structure of the 4000-amino-acid kinase DNA-PKcs and discovered an important new component PAXX, is currently investigating their interactions using cryo-EM. The Blundell Group has also produced widely used software packages, including Modeller (~11,200 citations) and Fugue (~1,400 citations) for protein modelling, and SDM and mCSM for predicting effects of mutations on protein stability and interactions. The Group now focuses on machine learning as well as databases to underpin drug discovery and to understand cancer and drug resistance. Blundell has developed new approaches to structure-guided and fragment-based drug discovery in Astex Therapeutics, now with breast cancer and urothelial carcinoma drugs on market. In academia, he has targeted Mycobacterium tuberculosis proteins in the Gates HIT-TB consortium, M. leprae for the American Leprosy Mission and M. abscessus for the Cystic Fibrosis Trust.